The survey comes amid an ongoing controversy over a fivefold increase in the price of lifesaving EpiPen anti-allergy devices, which now cost more than $600 for a pack of two auto-injectors.
But Mylan, which makes EpiPens, is just the latest drug company to draw the wrath of Congress and customers for its high prices.
Despite that fury, and past outrage over prescription drug costs, little if anything has changed in terms of policy.
Unlike many countries in Europe, the United States does not limit the prices that drugmakers can set. Reductions in drug costs come from insurance companies and other payors negotiating with pharma companies.
An article published last month by the JAMA Network of the Journal of the American Medical Association said per capita spending on prescription drugs in the United States "exceeds that in all other countries, largely driven by brand-name drug prices that have been increasing in recent years at rates far beyond the consumer price index."
In 2013, per capita U.S. prescription drug spending "was $858 compared with an average of $400 for 19 other industrialized nations," the JAMA article said.
"Although prices are often justified by the high cost of drug development, there is no evidence of an association between research and development costs and prices; rather, prescription drugs are priced in the United States primarily on the basis of what the market will bear," the authors wrote.